Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension

Vascular Pharmacology

Volumn 58, Issue 3, 2013, Pages 211-218

  Chen, Chien nien ^a   Watson, Geoffrey ^a   Zhao, Lan ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

CGMP; Pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; BERAPROST; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; CYCLIC NUCLEOTIDE GATED CHANNEL; ENDOTHELIN RECEPTOR; GUANYLATE CYCLASE; ILOPROST; MULTIDRUG RESISTANCE PROTEIN; NATRIURETIC FACTOR; NITRIC OXIDE; NITRITE; PHOSPHODIESTERASE; PHOSPHODIESTERASE V; PROSTACYCLIN; PROTEIN KINASE; RHO KINASE; SILDENAFIL; SITAXSENTAN; TADALAFIL; TETRAHYDROBIOPTERIN; TREPROSTINIL; VARDENAFIL;

ARTICLE; CELL FUNCTION; ENZYME INHIBITION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION;

ANIMALS; CYCLIC GMP; DRUG DESIGN; GUANYLATE CYCLASE; HUMANS; HYPERTENSION, PULMONARY; MOLECULAR TARGETED THERAPY; NITRIC OXIDE; PHOSPHORIC DIESTER HYDROLASES; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 84875371306     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2012.09.001     Document Type: Article

References (129)

1. Abe K., Shimokawa H., Morikawa K., Uwatoku T., Oi K., Matsumoto Y., Hattori T., Nakashima Y., Kaibuchi K., Sueishi K., Takeshit A. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ. Res. 2004, 94:385-393.
2. Allen S.W., Chatfield B.A., Koppenhafer S.A., Schaffer M.S., Wolfe R.R., Abman S.H. Circulating immunoreactive endothelin-1 in children with pulmonary hypertension. Association with acute hypoxic pulmonary vasoreactivity. Am. Rev. Respir. Dis. 1993, 148:519-522.
3. Arjona A.A., Hsu C.A., Wrenn D.S., Hill N.S. Effects of natriuretic peptides on vascular smooth-muscle cells derived from different vascular beds. Gen. Pharmacol. 1997, 28:387-392.
4. Badesch D.B., Raskob G.E., Elliott C.G., Krichman A.M., Farber H.W., Frost A.E., Barst R.J., Benza R.L., Liou T.G., Turner M., Giles S., Feldkircher K., Miller D.P., McGoon M.D. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010, 137:376-387.
5. Baliga R.S., Zhao L., Madhani M., Lopez-Torondel B., Visintin C., Selwood D., Wilkins M.R., MacAllister R.J., Hobbs A.J. Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2008, 178:861-869.
6. Baliga R.S., Milsom A.B., Ghosh S.M., Trinder S.L., MacAllister R.J., Ahluwalia A., Hobbs A.J. Dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase. Circulation 2012, 125:2922-2932.
7. Beavo J.A., Brunton L.L. Cyclic nucleotide research - still expanding after half a century. Nat. Rev. Mol. Cell Biol. 2002, 3:710-718.
8. Beghetti M., Habre W., Friedli B., Berner M. Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br. Heart J. 1995, 73:65-68.
9. Benigni A., Remuzzi G. Endothelin antagonists. Lancet 1999, 353:133-138.
10. Biel M., Michalakis S. Function and dysfunction of CNG channels: insights from channelopathies and mouse models. Mol. Neurobiol. 2007, 35:266-277.
11. Boon E.M., Huang S.H., Marletta M.A. A molecular basis for NO selectivity in soluble guanylate cyclase. Nat. Chem. Biol. 2005, 1:53-59.
12. Casey D.B., Badejo A.M., Dhaliwal J.S., Murthy S.N., Hyman A.L., Nossaman B.D., Kadowitz P.J. Pulmonary vasodilator responses to sodium nitrite are mediated by an allopurinol-sensitive mechanism in the rat. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H524-H533.
13. Casserly B., Klinger J.R. Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. Drug Des. Devel. Ther. 2009, 3:269-287.
14. Champion H.C., Bivalacqua T.J., Greenberg S.S., Giles T.D., Hyman A.L., Kadowitz P.J. Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13248-13253.
15. Chan S., Yan C. PDE1 isozymes, key regulators of pathological vascular remodeling. Curr. Opin. Pharmacol. 2011, 11:720-724.
16. Chockalingam A., Gnanavelu G., Venkatesan S., Elangovan S., Jagannathan V., Subramaniam T., Alagesan R., Dorairajan S. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int. J. Cardiol. 2005, 99:91-95.
17. Christman B.W., McPherson C.D., Newman J.H., King G.A., Bernard G.R., Groves B.M., Loyd J.E. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 1992, 327:70-75.
18. Corbin J.D., Turko I.V., Beasley A., Francis S.H. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur. J. Biochem. 2000, 267:2760-2767.
19. Corbin J.D., Beasley A., Blount M.A., Francis S.H. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem. Biophys. Res. Commun. 2005, 334:930-938.
20. Craven K.B., Zagotta W.N. CNG and HCN channels: two peas, one pod. Annu. Rev. Physiol. 2006, 68:375-401.
21. Cunnington C., Van A.T., Shirodaria C., Kylintireas I., Lindsay A.C., Lee J.M., Antoniades C., Margaritis M., Lee R., Cerrato R., Crabtree M.J., Francis J.M., Sayeed R., Ratnatunga C., Pillai R., Choudhury R.P., Neubauer S., Channon K.M. Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation 2012, 125:1356-1366.
22. Day R.W., Lynch J.M., Shaddy R.E., Orsmond G.S. Pulmonary vasodilatory effects of 12 and 60 parts per million inhaled nitric oxide in children with ventricular septal defect. Am. J. Cardiol. 1995, 75:196-198.
23. Dony E., Lai Y.J., Dumitrascu R., Pullamsetti S.S., Savai R., Ghofrani H.A., Weissmann N., Schudt C., Flockerzi D., Seeger W., Grimminger F., Schermuly R.T. Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition. Eur. Respir. J. 2008, 31:599-610.
24. Duda T., Goraczniak R.M., Sharma R.K. Core sequence of ATP regulatory module in receptor guanylate cyclases. FEBS Lett. 1993, 315:143-148.
25. Dumitrascu R., Weissmann N., Ghofrani H.A., Dony E., Beuerlein K., Schmidt H., Stasch J.P., Gnoth M.J., Seeger W., Grimminger F., Schermuly R.T. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006, 113:286-295.
26. Ellmers L.J., Knowles J.W., Kim H.S., Smithies O., Maeda N., Cameron V.A. Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis. Am. J. Physiol. Heart Circ. Physiol. 2002, 283:H707-H714.
27. Emori T., Hirata Y., Imai T., Eguchi S., Kanno K., Marumo F. Cellular mechanism of natriuretic peptides-induced inhibition of endothelin-1 biosynthesis in rat endothelial cells. Endocrinology 1993, 133:2474-2480.
28. Evgenov O.V., Pacher P., Schmidt P.M., Hasko G., Schmidt H.H., Stasch J.P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov. 2006, 5:755-768.
29. Fagan K.A., McMurtry I.F., Rodman D.M. Role of endothelin-1 in lung disease. Respir. Res. 2001, 2:90-101.
30. Feil R., Lohmann S.M., de J.H., Walter U., Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ. Res. 2003, 93:907-916.
31. Francis S.H., Blount M.A., Zoraghi R., Corbin J.D. Molecular properties of mammalian proteins that interact with cGMP: protein kinases, cation channels, phosphodiesterases, and multi-drug anion transporters. Front. Biosci. 2005, 10:2097-2117.
32. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A., Grimminger F., Kurzyna M., Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2005, 353:2148-2157.
33. Galie N., Brundage B.H., Ghofrani H.A., Oudiz R.J., Simonneau G., Safdar Z., Shapiro S., White R.J., Chan M., Beardsworth A., Frumkin L., Barst R.J. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903.
34. Galie N., Manes A., Negro L., Palazzini M., Bacchi-Reggiani M.L., Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur. Heart J. 2009, 30:394-403.
35. Ghofrani H.A., Wiedemann R., Rose F., Olschewski H., Schermuly R.T., Weissmann N., Seeger W., Grimminger F. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. 2002, 136:515-522.
36. Ghofrani H.A., Rose F., Schermuly R.T., Olschewski H., Wiedemann R., Kreckel A., Weissmann N., Ghofrani S., Enke B., Seeger W., Grimminger F. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2003, 42:158-164.
37. Ghofrani H.A., Hoeper M.M., Halank M., Meyer F.J., Staehler G., Behr J., Ewert R., Weimann G., Grimminger F. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur. Respir. J. 2010, 36:792-799.
38. Giaid A., Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 1995, 333:214-221.
39. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., Kimura S., Masaki T., Duguid W.P., Stewart D.J. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 1993, 328:1732-1739.
40. Girgis R.E., Champion H.C., Diette G.B., Johns R.A., Permutt S., Sylvester J.T. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am. J. Respir. Crit. Care Med. 2005, 172:352-357.
41. Goraczniak R.M., Duda T., Sharma R.K. A structural motif that defines the ATP-regulatory module of guanylate cyclase in atrial natriuretic factor signalling. Biochem. J. 1992, 282(Pt 2):533-537.
42. Hara Y., Sassi Y., Guibert C., Gambaryan N., Dorfmuller P., Eddahibi S., Lompre A.M., Humbert M., Hulot J.S. Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J. Clin. Invest. 2011, 121:2888-2897.
43. Hassoun P.M., Thappa V., Landman M.J., Fanburg B.L. Endothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells. Proc. Soc. Exp. Biol. Med. 1992, 199:165-170.
44. Haydar S., Sarti J.F., Grisoni E.R. Intravenous vasoactive intestinal polypeptide lowers pulmonary-to-systemic vascular resistance ratio in a neonatal piglet model of pulmonary arterial hypertension. J. Pediatr. Surg. 2007, 42:758-764.
45. Hofmann F. The biology of cyclic GMP-dependent protein kinases. J. Biol. Chem. 2005, 280:1-4.
46. Humbert M., Sitbon O., Chaouat A., Bertocchi M., Habib G., Gressin V., Yaici A., Weitzenblum E., Cordier J.F., Chabot F., Dromer C., Pison C., Reynaud-Gaubert M., Haloun A., Laurent M., Hachulla E., Cottin V., Degano B., Jais X., Montani D., Souza R., Simonneau G. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010, 122:156-163.
47. Hunter C.J., Dejam A., Blood A.B., Shields H., Kim-Shapiro D.B., Machado R.F., Tarekegn S., Mulla N., Hopper A.O., Schechter A.N., Power G.G., Gladwin M.T. Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nat. Med. 2004, 10:1122-1127.
48. Ishikura K., Yamada N., Ito M., Ota S., Nakamura M., Isaka N., Nakano T. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ. J. 2006, 70:174-178.
49. Kakishita M., Nishikimi T., Okano Y., Satoh T., Kyotani S., Nagaya N., Fukushima K., Nakanishi N., Takishita S., Miyata A., Kangawa K., Matsuo H., Kunieda T. Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin. Sci. (Lond.) 1999, 96:33-39.
50. Kamisaki Y., Saheki S., Nakane M., Palmieri J.A., Kuno T., Chang B.Y., Waldman S.A., Murad F. Soluble guanylate cyclase from rat lung exists as a heterodimer. J. Biol. Chem. 1986, 261:7236-7241.
51. Kass D.A., Takimoto E., Nagayama T., Champion H.C. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc. Res. 2007, 75:303-314.
52. Kato J., Tsuruda T., Kita T., Kitamura K., Eto T. Adrenomedullin: a protective factor for blood vessels. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2480-2487.
53. Kaupp U.B., Seifert R. Cyclic nucleotide-gated ion channels. Physiol. Rev. 2002, 82:769-824.
54. Khoo J.P., Zhao L., Alp N.J., Bendall J.K., Nicoli T., Rockett K., Wilkins M.R., Channon K.M. Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation 2005, 111:2126-2133.
55. Klinger J.R. Tadalafil for the treatment of pulmonary arterial hypertension. Expert Rev. Respir. Med. 2011, 5:315-328.
56. Klinger J.R., Warburton R.R., Pietras L.A., Smithies O., Swift R., Hill N.S. Genetic disruption of atrial natriuretic peptide causes pulmonary hypertension in normoxic and hypoxic mice. Am. J. Physiol. 1999, 276:L868-L874.
57. Klinger J.R., Thaker S., Houtchens J., Preston I.R., Hill N.S., Farber H.W. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 2006, 129:417-425.
58. Komalavilas P., Shah P.K., Jo H., Lincoln T.M. Activation of mitogen-activated protein kinase pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells. J. Biol. Chem. 1999, 274:34301-34309.
59. Koyama H., Bornfeldt K.E., Fukumoto S., Nishizawa Y. Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J. Cell. Physiol. 2001, 186:1-10.
60. Kuhn M. Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ. Res. 2003, 93:700-709.
61. Kurose H., Inagami T., Ui M. Participation of adenosine 5'-triphosphate in the activation of membrane-bound guanylate cyclase by the atrial natriuretic factor. FEBS Lett. 1987, 219:375-379.
62. Leuchte H.H., Schwaiblmair M., Baumgartner R.A., Neurohr C.F., Kolbe T., Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 2004, 125:580-586.
63. Leuchte H.H., Baezner C., Baumgartner R.A., Bevec D., Bacher G., Neurohr C., Behr J. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur. Respir. J. 2008, 32:1289-1294.
64. Lundberg J.O., Weitzberg E., Gladwin M.T. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat. Rev. Drug Discov. 2008, 7:156-167.
65. Ma X., Sayed N., Beuve A., van den Akker F. NO and CO differentially activate soluble guanylyl cyclase via a heme pivot-bend mechanism. EMBO J. 2007, 26:578-588.
66. Ma X., Sayed N., Baskaran P., Beuve A., van den Akker F. PAS-mediated dimerization of soluble guanylyl cyclase revealed by signal transduction histidine kinase domain crystal structure. J. Biol. Chem. 2008, 283:1167-1178.
67. Macchia A., Marchioli R., Tognoni G., Scarano M., Marfisi R., Tavazzi L., Rich S. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am. Heart J. 2010, 159:245-257.
68. MacLean M.R., Johnston E.D., Mcculloch K.M., Pooley L., Houslay M.D., Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J. Pharmacol. Exp. Ther. 1997, 283:619-624.
69. Matsui H., Shimosawa T., Itakura K., Guanqun X., Ando K., Fujita T. Adrenomedullin can protect against pulmonary vascular remodeling induced by hypoxia. Circulation 2004, 109:2246-2251.
70. McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002, 106:1477-1482.
71. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 1993, 329:2002-2012.
72. Murad F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N. Engl. J. Med. 2006, 355:2003-2011.
73. Murray F., Patel H.H., Suda R.Y., Zhang S., Thistlethwaite P.A., Yuan J.X., Insel P.A. Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292:L294-L303.
74. Nagaya N., Nishikimi T., Uematsu M., Satoh T., Oya H., Kyotani S., Sakamaki F., Ueno K., Nakanishi N., Miyatake K., Kangawa K. Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension. Heart 2000, 84:653-658.
75. Nagaya N., Okumura H., Uematsu M., Shimizu W., Ono F., Shirai M., Mori H., Miyatake K., Kangawa K. Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats. Am. J. Physiol. Heart Circ. Physiol. 2003, 285:H2125-H2131.
76. Nagaya N., Kyotani S., Uematsu M., Ueno K., Oya H., Nakanishi N., Shirai M., Mori H., Miyatake K., Kangawa K. Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 2004, 109:351-356.
77. Nandi M., Miller A., Stidwill R., Jacques T.S., Lam A.A., Haworth S., Heales S., Vallance P. Pulmonary hypertension in a GTP-cyclohydrolase 1-deficient mouse. Circulation 2005, 111:2086-2090.
78. Nishida H., Horio T., Suzuki Y., Iwashima Y., Kamide K., Kangawa K., Kawano Y. Plasma adrenomedullin as an independent predictor of future cardiovascular events in high-risk patients: comparison with C-reactive protein and adiponectin. Peptides 2008, 29:599-605.
79. O'Callaghan D.S., Savale L., Montani D., Jais X., Sitbon O., Simonneau G., Humbert M. Treatment of pulmonary arterial hypertension with targeted therapies. Nat. Rev. Cardiol. 2011, 8:526-538.
80. Oka M., Homma N., Taraseviciene-Stewart L., Morris K.G., Kraskauskas D., Burns N., Voelkel N.F., McMurtry I.F. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ. Res. 2007, 100:923-929.
81. Oka M., Fagan K.A., Jones P.L., McMurtry I.F. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br. J. Pharmacol. 2008, 155:444-454.
82. Omori K., Kotera J. Overview of PDEs and their regulation. Circ. Res. 2007, 100:309-327.
83. Petkov V., Mosgoeller W., Ziesche R., Raderer M., Stiebellehner L., Vonbank K., Funk G.C., Hamilton G., Novotny C., Burian B., Block L.H. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. 2003, 111:1339-1346.
84. Pfeifer A., Klatt P., Massberg S., Ny L., Sausbier M., Hirneiss C., Wang G.X., Korth M., Aszodi A., Andersson K.E., Krombach F., Mayerhofer A., Ruth P., Fassler R., Hofmann F. Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J. 1998, 17:3045-3051.
85. Phillips P.G., Long L., Wilkins M.R., Morrell N.W. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 288:L103-L115.
86. Pullamsetti S.S., Savai R., Schaefer M.B., Wilhelm J., Ghofrani H.A., Weissmann N., Schudt C., Fleming I., Mayer K., Leiper J., Seeger W., Grimminger F., Schermuly R.T. cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases. Circulation 2011, 123:1194-1204.
87. Rao Y.J., Xi L. Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Acta Pharmacol. Sin. 2009, 30:1-24.
88. Robbins I.M., Hemnes A.R., Gibbs J.S., Christman B.W., Howard L., Meehan S., Cabrita I., Gonzalez R., Oyler T., Zhao L., Du R.H., Mendes L.A., Wilkins M.R. Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. Exp. Lung Res. 2011, 37:26-34.
89. Roberts J.D., Lang P., Bigatello L.M., Vlahakes G.J., Zapol W.M. Inhaled nitric oxide in congenital heart disease. Circulation 1993, 87:447-453.
90. Rubin L.J., Mendoza J., Hood M., McGoon M., Barst R., Williams W.B., Diehl J.H., Crow J., Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann. Intern. Med. 1990, 112:485-491.
91. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., Pulido T., Frost A., Roux S., Leconte I., Landzberg M., Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2002, 346:896-903.
92. Rybalkin S.D., Rybalkina I.G., Shimizu-Albergine M., Tang X.B., Beavo J.A. PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J. 2003, 22:469-478.
93. Said S.I., Hamidi S.A., Dickman K.G., Szema A.M., Lyubsky S., Lin R.Z., Jiang Y.P., Chen J.J., Waschek J.A., Kort S. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 2007, 115:1260-1268.
94. Sarkar R., Webb R.C. Does nitric oxide regulate smooth muscle cell proliferation? A critical appraisal. J. Vasc. Res. 1998, 35:135-142.
95. Sassi Y., Lipskaia L., Vandecasteele G., Nikolaev V.O., Hatem S.N., Cohen A.F., Russel F.G., Mougenot N., Vrignaud C., Lechat P., Lompre A.M., Hulot J.S. Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation. J. Clin. Invest. 2008, 118:2747-2757.
96. Sauzeau V., Le J.H., Cario-Toumaniantz C., Smolenski A., Lohmann S.M., Bertoglio J., Chardin P., Pacaud P., Loirand G. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J. Biol. Chem. 2000, 275:21722-21729.
97. Sauzeau V., Rolli-Derkinderen M., Marionneau C., Loirand G., Pacaud P. RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. J. Biol. Chem. 2003, 278:9472-9480.
98. Sawada N., Itoh H., Yamashita J., Doi K., Inoue M., Masatsugu K., Fukunaga Y., Sakaguchi S., Sone M., Yamahara K., Yurugi T., Nakao K. cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem. Biophys. Res. Commun. 2001, 280:798-805.
99. Schermuly R.T., Kreisselmeier K.P., Ghofrani H.A., Yilmaz H., Butrous G., Ermert L., Ermert M., Weissmann N., Rose F., Guenther A., Walmrath D., Seeger W., Grimminger F. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 2004, 169:39-45.
100. Schermuly R.T., Pullamsetti S.S., Kwapiszewska G., Dumitrascu R., Tian X., Weissmann N., Ghofrani H.A., Kaulen C., Dunkern T., Schudt C., Voswinckel R., Zhou J., Samidurai A., Klepetko W., Paddenberg R., Kummer W., Seeger W., Grimminger F. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation 2007, 115:2331-2339.
101. Schermuly R.T., Stasch J.P., Pullamsetti S.S., Middendorff R., Muller D., Schluter K.D., Dingendorf A., Hackemack S., Kolosionek E., Kaulen C., Dumitrascu R., Weissmann N., Mittendorf J., Klepetko W., Seeger W., Ghofrani H.A., Grimminger F. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur. Respir. J. 2008, 32:881-891.
102. Schermuly R.T., Ghofrani H.A., Wilkins M.R., Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat. Rev. Cardiol. 2011, 8:443-455.
103. Schermuly R.T., Janssen W., Weissmann N., Stasch J.P., Grimminger F., Ghofrani H.A. Riociguat for the treatment of pulmonary hypertension. Expert Opin. Investig. Drugs 2011, 20:567-576.
104. Sebkhi A., Strange J.W., Phillips S.C., Wharton J., Wilkins M.R. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 2003, 107:3230-3235.
105. Sim J.Y. Nitric oxide and pulmonary hypertension. Korean J. Anesthesiol. 2010, 58:4-14.
106. Simonneau G., Rubin L.J., Galie N., Barst R.J., Fleming T.R., Frost A.E., Engel P.J., Kramer M.R., Burgess G., Collings L., Cossons N., Sitbon O., Badesch D.B. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann. Intern. Med. 2008, 149:521-530.
107. Sparacino-Watkins C.E., Lai Y.C., Gladwin M.T. Nitrate-nitrite-nitric oxide pathway in pulmonary arterial hypertension therapeutics. Circulation 2012, 125:2824-2826.
108. Surks H.K. cGMP-dependent protein kinase I and smooth muscle relaxation: a tale of two isoforms. Circ. Res. 2007, 101:1078-1080.
109. Thony B., Auerbach G., Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem. J. 2000, 347(Pt 1):1-16.
110. Tuder R.M., Cool C.D., Geraci M.W., Wang J., Abman S.H., Wright L., Badesch D., Voelkel N.F. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 1999, 159:1925-1932.
111. Turanlahti M., Pesonen E., Pohjavuori M., Lassus P., Fyhrquist F., Andersson S. Plasma cyclic guanosine monophosphate reflecting the severity of persistent pulmonary hypertension of the newborn. Biol. Neonate 2001, 80:107-112.
112. Vachiery J.L. Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy. Adv. Ther. 2011, 28:251-269.
113. van Aubel R.A., Smeets P.H., Peters J.G., Bindels R.J., Russel F.G. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 2002, 13:595-603.
114. Vasquez-Vivar J., Kalyanaraman B., Martasek P., Hogg N., Masters B.S., Karoui H., Tordo P., Pritchard K.A. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:9220-9225.
115. Wahl-Schott C., Biel M. HCN channels: structure, cellular regulation and physiological function. Cell. Mol. Life Sci. 2009, 66:470-494.
116. Weber S., Bernhard D., Lukowski R., Weinmeister P., Worner R., Wegener J.W., Valtcheva N., Feil S., Schlossmann J., Hofmann F., Feil R. Rescue of cGMP kinase I knockout mice by smooth muscle specific expression of either isozyme. Circ. Res. 2007, 101:1096-1103.
117. Wegener J.W., Nawrath H., Wolfsgruber W., Kuhbandner S., Werner C., Hofmann F., Feil R. cGMP-dependent protein kinase I mediates the negative inotropic effect of cGMP in the murine myocardium. Circ. Res. 2002, 90:18-20.
118. Wharton J., Strange J.W., Moller G.M., Growcott E.J., Ren X., Franklyn A.P., Phillips S.C., Wilkins M.R. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am. J. Respir. Crit. Care Med. 2005, 172:105-113.
119. Wielinga P.R., van der Heijden I., Reid G., Beijnen J.H., Wijnholds J., Borst P. Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J. Biol. Chem. 2003, 278:17664-17671.
120. Wojciak-Stothard B. New drug targets for pulmonary hypertension: Rho GTPases in pulmonary vascular remodelling. Postgrad. Med. J. 2008, 84:348-353.
121. Wolfsgruber W., Feil S., Brummer S., Kuppinger O., Hofmann F., Feil R. A proatherogenic role for cGMP-dependent protein kinase in vascular smooth muscle cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:13519-13524.
122. Xia Y., Tsai A.L., Berka V., Zweier J.L. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J. Biol. Chem. 1998, 273:25804-25808.
123. Zaccolo M., Movsesian M.A. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ. Res. 2007, 100:1569-1578.
124. Zhang M., Kass D.A. Phosphodiesterases and cardiac cGMP: evolving roles and controversies. Trends Pharmacol. Sci. 2011, 32:360-365.
125. Zhao L., Brown L.A., Owji A.A., Nunez D.J., Smith D.M., Ghatei M.A., Bloom S.R., Wilkins M.R. Adrenomedullin activity in chronically hypoxic rat lungs. Am. J. Physiol. 1996, 271:H622-H629.
126. Zhao L., Mason N.A., Morrell N.W., Kojonazarov B., Sadykov A., Maripov A., Mirrakhimov M.M., Aldashev A., Wilkins M.R. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001, 104:424-428.
127. Zhao L., Mason N.A., Strange J.W., Walker H., Wilkins M.R. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity. Circulation 2003, 107:234-237.
128. Zoraghi R., Bessay E.P., Corbin J.D., Francis S.H. Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J. Biol. Chem. 2005, 280:12051-12063.
129. Zuckerbraun B.S., Shiva S., Ifedigbo E., Mathier M.A., Mollen K.P., Rao J., Bauer P.M., Choi J.J., Curtis E., Choi A.M., Gladwin M.T. Nitrite potently inhibits hypoxic and inflammatory pulmonary arterial hypertension and smooth muscle proliferation via xanthine oxidoreductase-dependent nitric oxide generation. Circulation 2010, 121:98-109.